These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1647321)

  • 1. Effect of the kappa-receptor agonist, U-50,488H, on cerebral ischemia-induced impairment of working memory assessed in rats by a three-panel runway task.
    Ohno M; Yamamoto T; Ueki S
    Eur J Pharmacol; 1991 Feb; 193(3):357-61. PubMed ID: 1647321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U-50,488H, a kappa-opioid receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice.
    Itoh J; Ukai M; Kameyama T
    Brain Res; 1993 Aug; 619(1-2):223-8. PubMed ID: 8397052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
    Pugsley MK; Penz WP; Walker MJ; Wong TM
    Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
    Fukagawa Y; Katz JL; Suzuki T
    Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
    Czlonkowski A; Millan MJ; Herz A
    Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
    [No Abstract]   [Full Text] [Related]  

  • 6. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of U-50,488H analogs for neuroprotective activity in the gerbil.
    Contreras PC; Ragan DM; Bremer ME; Lanthorn TH; Gray NM; Iyengar S; Jacobson AE; Rice KC; de Costa BR
    Brain Res; 1991 Apr; 546(1):79-82. PubMed ID: 1649669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.
    Ukai M; Kameyama T
    Brain Res; 1985 Jul; 337(2):352-6. PubMed ID: 2992682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
    Bhargava HN; Ramarao P; Gulati A
    Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions.
    Ohno M; Yamamoto T; Ueki S
    Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic administration of U-50,488H, a kappa-opioid receptor agonist, on central dopamine D2 receptors of the rat.
    Veeranna ; Reddy PL; Bhargava HN
    Eur J Pharmacol; 1993 Apr; 235(1):23-30. PubMed ID: 8390939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
    Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
    Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
    Ho BY; Takemori AE
    J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats.
    Hiramatsu M; Murasawa H; Nabeshima T; Kameyama T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):858-67. PubMed ID: 9495843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The site of anti-arthritic action of the kappa-opioid, U-50, 488H, in adjuvant arthritis: importance of local administration.
    Wilson JL; Nayanar V; Walker JS
    Br J Pharmacol; 1996 Aug; 118(7):1754-60. PubMed ID: 8842441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a kappa-receptor agonist, U-50,488H, on the release of endogenous brain dopamine.
    Clow DW; Jhamandas K
    Can J Physiol Pharmacol; 1988 Feb; 66(2):128-33. PubMed ID: 2836044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
    Bhargava HN; Gulati A; Ramarao P
    J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
    Bhargava HN; Gulati A; Rahmani NH
    Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction between kappa-opioid agonist, U-50, 488H, and kainic acid: behavioral and histological assessments.
    Lason W; Simpson JN; McGinty JF
    Brain Res; 1989 Mar; 482(2):333-9. PubMed ID: 2539886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection and functional recovery conferred by administration of kappa- and delta 1-opioid agonists in a rat model of global ischemia.
    Charron C; Messier C; Plamondon H
    Physiol Behav; 2008 Feb; 93(3):502-11. PubMed ID: 18031772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.